L2 DIAGNOSTICS, LLC

Basic Information

BOX 8175
NEW HAVEN, CT, 06530-0175

Company Profile

n/a

Additional Details

Field Value
DUNS: 142406110
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids

    Amount: $250,298.00

    DESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; h ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Sterculic Acid Analogs to Inhibit Macular Degeneration

    Amount: $224,700.00

    ABSTRACT The long-term product goal of this project is a small molecule therapeutic for choroidal neovascularization (CNV, the hallmark of wet age-related macular degradation), an abnormal growth o ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions

    Amount: $599,996.00

    DESCRIPTION (provided by applicant): This proposal seeks to develop a novel vaccine against Lyme disease -- by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from ...

    STTR Phase I 2014 Department of Health and Human Services
  4. RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Leptospirosis, a zoonotic disease, is an important public health problem worldwide. It is caused by spirochete bacteria belonging to nine species and more than 200 ...

    STTR Phase I 2014 Department of Health and Human Services
  5. Measurement of Beta Cell Death in Diabetes

    Amount: $1,348,103.00

    DESCRIPTION (provided by applicant): All forms of diabetes are characterized by the death of insulin producing ? cells. In Type 1 diabetes (T1D) this leads to the reliance on exogenous insulin for sur ...

    STTR Phase II 2014 Department of Health and Human Services
  6. A serologic assay to measure successful Lyme borreliosis antibiotic therapy

    Amount: $2,642,728.00

    DESCRIPTION (provided by applicant): Lyme disease (LD) caused by the Ixodes tick-borne spirochete Borrelia burgdorferi (Bb), is the most common vector-borne disease in the United States. Despite publi ...

    SBIR Phase II 2014 Department of Health and Human Services
  7. Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens

    Amount: $1,655,122.00

    DESCRIPTION (provided by applicant): Current testing for Lyme disease is suboptimal because it requires two assay platforms, including one with subjective interpretation of results, and because it has ...

    SBIR Phase II 2014 Department of Health and Human Services
  8. A Lyme disease vaccine using newly identified in-vivo expressed antigens

    Amount: $595,406.00

    DESCRIPTION (provided by applicant): Lyme disease is the most common arthropod-borne disease in the United States, with over 38,000 confirmed and probable cases reported in 2009. The causative agent o ...

    SBIR Phase I 2013 Department of Health and Human Services
  9. Small Molecule Antiviral Agents Against Flaviviruses

    Amount: $996,931.00

    Flaviviruses, and dengue viruses in particular, are significant human pathogens. No vaccine or specific therapeutic agent is available against West Nile and dengue viruses. Our goal is to develop pe ...

    SBIR Phase II 2013 Department of DefenseArmyDepartment of Defense
  10. Therapeutic Inhibition of MIF in Rheumatoid Arthritis

    Amount: $988,799.00

    DESCRIPTION (provided by applicant): The long-term product goal of this project is a small molecule therapeutic to treat rheumatoid arthritis (RA), which acts by reducing the inflammatory response tri ...

    SBIR Phase II 2012 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government